Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Receivables (2018 - 2023)

Moleculin Biotech (MBRX) has 5 years of Receivables data on record, last reported at $12000.0 in Q2 2023.

  • For Q2 2023, Receivables changed N/A year-over-year to $12000.0; the TTM value through Jun 2023 reached $12000.0, changed N/A, while the annual FY2022 figure was $22000.0, N/A changed from the prior year.
  • Receivables reached $12000.0 in Q2 2023 per MBRX's latest filing, down from $22000.0 in the prior quarter.
  • Across five years, Receivables topped out at $316000.0 in Q3 2019 and bottomed at $1000.0 in Q1 2020.
  • Average Receivables over 4 years is $72400.0, with a median of $12000.0 recorded in 2023.
  • The widest YoY moves for Receivables: up 80.36% in 2019, down 80.36% in 2019.
  • A 4-year view of Receivables shows it stood at $11000.0 in 2019, then plummeted by 90.91% to $1000.0 in 2020, then skyrocketed by 2100.0% to $22000.0 in 2022, then plummeted by 45.45% to $12000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Receivables were $12000.0 in Q2 2023, $22000.0 in Q4 2022, and $1000.0 in Q1 2020.